Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative medications operate by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these compounds increase insulin secretion and reduce glu

The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting substantial weight reduction – they exhibit intriguing variations in t